Clascoterone vs RU58841: Mechanism, Evidence and Key Differences
RU58841 is a non-steroidal androgen receptor antagonist developed in the 1990s and abandoned before human efficacy trials were completed. It remains widely discussed because its mechanism is exactly the one people want. Clascoterone reached the same mechanistic goal and completed regulatory-grade trials.
Similar target, different molecules
Both compounds compete with DHT at the androgen receptor in scalp tissue, and both were designed to act locally rather than systemically.
Clascoterone is a steroidal ester of cortexolone, hydrolysed to an inactive metabolite once it enters circulation. RU58841 is a non-steroidal anilide whose human pharmacokinetics and long-term systemic behaviour were never fully characterised in published trials.
The evidence gap
| Clascoterone | RU58841 | |
|---|---|---|
| Human Phase III data | Yes (acne, >1,465 patients) | None published |
| Regulatory approval | Yes, as 1% cream (acne, US) | None — not approved anywhere |
| Manufacturing standard | GMP pharmaceutical production | Research-chemical supply, unverified |
| Known safety profile | Characterised in trials | Largely anecdotal |
| Purity assurance | Batch controlled | Buyer-dependent |
Why the supply chain is the real difference
RU58841 is sold as a research chemical, not a finished product. Purity, concentration accuracy, solvent quality and contamination control vary between suppliers and between batches, and there is no regulator verifying any of it.
That uncertainty applies to both efficacy and safety: an unverified powder dissolved in an unverified vehicle cannot produce a predictable dose at the follicle.
Conclusion
If the goal is topical androgen receptor antagonism with a documented human safety record and controlled manufacturing, clascoterone is the compound that actually completed that path. RU58841's mechanism is plausible; its evidence and quality assurance are not established.
References
- Battmann T, et al. RU58841, a non-steroidal antiandrogen: preclinical characterisation. — Journal of Steroid Biochemistry and Molecular Biology
- Hebert A, et al. Topical Clascoterone Cream 1%: Two Phase 3 Randomized Clinical Trials. — JAMA Dermatology, 2020
- Risks of research-chemical use in dermatology. — PubMed — review literature
This library is educational. For the product itself — formulation, routine, pricing and shipping terms — return to the main website.
View the product